Vice President, Chief Technology Officer
Martin Smith leads the technology journey of Cytiva. He “returned” to the company in 2020, following several years with Pall Corporation and Danaher, before which he held leadership positions in Marketing and R&D with a Cytiva predecessor company Whatman.
Martin is a keen believer in new product strategies that link customer needs to market share gain, by building on innovation strength, technology conversion, and organizational leadership. Martin is a strong advocate of releasing the potential of teams from several functions who work together towards goals that directly reflect the company’s strategic priorities.
While CTO of Pall Corporation from 2014-2020, he and team implemented Research and Product Development strategies, governance, framework, and many, many new product launches which directly contributed to company core growth. Upon Danaher’s acquisition of Pall Corporation in 2015 he helped establish and implement many of the DBS tools and metrics that are now associated with a progressive ‘Holistic View of Innovation’ (HVI) and used across all of Danaher.
He served in various leadership roles at Pall from 2006-2014. Martin has held several technical and product development positions at various diagnostics and laboratory supply companies in both the US and Europe such as R&D Systems Inc. and served as VP of Clinical Diagnostics at Intelligent MDx Inc. a novel symptom-based Point of Care (POC) diagnostics company.
Martin earned his Ph.D. in Biochemistry from University College London, UK and is the holder of multiple US granted patents in the area of separations science. He has been an active Industrial Liaison Board Member for NYU-Poly, Brooklyn, NY since 2013.
Martin is a transplant from Britain and has lived in several locations in the US over 25 years and currently resides on Long Island, New York with his wife and two teenage children.